Browsing by Author "Merola, J. F."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Developing classification criteria for skin-predominant dermatomyositis: the Delphi process
    (Wiley, 2020-02) Concha, J. S. S.; Pena, S.; Gaffney, R. G.; Patel, B.; Tarazi, M.; Kushner, C. J.; Merola, J. F.; Fiorentino, D.; Dutz, J. P.; Goodfield, M.; Nyberg, F.; Volc-Platzer, B.; Fujimoto, M.; Ang, C. C.; Werth, V. P.; The Skin Myositis Delphi Group; Dermatology, School of Medicine
    Background The European League Against Rheumatism/American College of Rheumatology classification criteria for inflammatory myopathies are able to classify patients with skin-predominant dermatomyositis (DM). However, approximately 25% of patients with skin-predominant DM do not meet two of the three hallmark skin signs and fail to meet the criteria. Objectives To develop a set of skin-focused classification criteria that will distinguish cutaneous DM from mimickers and allow a more inclusive definition of skin-predominant disease. Methods An extensive literature review was done to generate items for the Delphi process. Items were grouped into categories of distribution, morphology, symptoms, antibodies, histology and contextual factors. Using REDCap™, participants rated these items in terms of appropriateness and distinguishing ability from mimickers. The relevance score ranged from 1 to 100, and the median score determined a rank-ordered list. A prespecified median score cut-off was decided by the steering committee and the participants. There was a pre-Delphi and two rounds of actual Delphi. Results There were 50 participating dermatologists and rheumatologists from North America, South America, Europe and Asia. After a cut-off score of 70 during the first round, 37 of the initial 54 items were retained and carried over to the next round. The cut-off was raised to 80 during round two and a list of 25 items was generated. Conclusions This project is a key step in the development of prospectively validated classification criteria that will create a more inclusive population of patients with DM for clinical research.
  • Thumbnail Image
    Item
    Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
    (Wiley, 2019-08) Johnson, C. M.; Fitch, K.; Merola, J. F.; Han, J.; Qureshi, A. A.; Li, W.-Q.; Epidemiology, School of Public Health